The global high content screening market is estimated to grow at a CAGR of 10.3% from 2017 to 2022 to reach USD 909.0 Million by 2022. Market growth can be attributed to the need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.

In this report the market is segmented on the basis of product, application, and end user. This report also provides market information on major regional segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The report provides an insight on the HCS product matrix which presents comparative analysis of product portfolios of leading market players. Moreover, the vendor benchmarking provided in the report illustrates the comparison between the geographic and product strength of top companies.

Get Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=42710391

The global high-content screening market is dominated by large lifesciences market players such as GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer Inc. (U.S.), and Becton, Dickinson & Company (U.S.). The leading players are continuously developing new and innovative products to maintain their shares in the HCS market.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]